Imaging Biometrics Expands Distribution

Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI) has renewed its distribution agreement with GE HealthCare. This agreement aims to expand the distribution of IB's advanced imaging solutions. GE HealthCare will now sell IB Neuro and IB Delta T1 platforms directly to both existing and new customers.

IB Neuro and IB Delta T1 maps are frequently used together to assist in diagnosing, planning, and monitoring treatment response for brain tumor patients. Delta T1 maps provide objective and rapid delineation of contrast-enhancing regions, while IB Neuro generates magnetic resonance (MR) perfusion images that accurately measure relative cerebral blood volume (rCBV) using a proven contrast leakage correction algorithm. IB Neuro's rCBV perfusion maps, derived from dynamic susceptibility contrast MRI (DSC-MRI), are used for tumor assessment and have demonstrated the ability to distinguish between true tumor regrowth and normal treatment effects. Both maps are automatically generated and quantitative, allowing for direct longitudinal comparison to assess tumoral changes.

"This global distribution arrangement allows us to introduce our products to GE HealthCare's extensive customer base more rapidly," said Michael Schmainda, CEO of IB. "We are excited about the immediate opportunities this creates for GE HealthCare's sales and marketing teams."

Katie Anderson, Global MR Visualization Product Manager added, "We are excited to expand our collaboration with Imaging Biometrics to enable access for our customers to these clinically important capabilities."

The revised agreement aims to accelerate the adoption of IB's innovative imaging solutions, benefiting healthcare providers and patients alike.

The Directors of the Company accept responsibility for the contents of this announcement.